F-18 mefway is a novel serotonin-1A receptor ligand that could one day be used to image neurodegenerative disease and psychiatric disorders, according to a story published Nov. 13 in the Journal of Nuclear Medicine . {read more here}

A novel striatal positron emission tomography (PET) imaging biomarker may identify individuals with early Huntington’s disease (HD), hint results of a small pilot study. {read more here}

While CT and MR are still the mainstays of detecting ischemic stroke, several SPECT and PET imaging techniques have been developed and are on the way to add comprehensive clinical information in the case of cerebrovascular disease. With this in mind, hybrid imaging such as PET/MR could provide a best-possible map of variables involved in stroke, according to a review published Oct. 9 in the Journal of Nuclear Medicine . {read more here}

Radiopharmaceutical firm Cellectar Biosciences said that a new study published in PLOS One found that its phospholipid ether (PLE) analog agents showed efficacy for detecting colorectal cancer.

In the study, published online October 6, a research team led by Dr. Dustin Deming of the University of Wisconsin determined that Cellectar’s CLR1502 agent accumulated in intestinal tumors and was able to distinguish malignant from nonmalignant tissues in an animal model of colon cancer. It could also highlight regional lymph nodes, Cellectar said.

In addition, the researchers shared results of a phase I clinical trial for Cellectar’s iodine-131 CLR1404 investigational PET tracer/therapeutic agent. The agent accumulated in human colon cancer metastases, showing its potential value in colorectal cancer treatment and also as a PET imaging agent, Cellectar said. {read more here}